Abstract
Pluripotent stem cells (PSCs) have long been associated with tumorigenic risk, primarily due to their capacity to form teratomas in preclinical models. However, these findings are predominantly derived from studies conducted in immunocompromised hosts. Emerging evidence suggests that in immunocompetent environments, PSCs are efficiently cleared and do not form tumors. Furthermore, increasing data indicate that PSC-derived factors—particularly exosomes and microRNAs—may exert anti-tumor effects by reprogramming malignant cells and modulating oncogenic signaling pathways. This review reexamines the tumorigenicity paradigm, highlighting the role of host immunity, paracrine signaling mechanisms, and the emerging concept of PSC-based cancer prevention. Clinical observations and culture-related safety considerations are also discussed. Collectively, these findings support a more nuanced understanding of PSC safety and suggest potential therapeutic and preventive applications in oncology.
Introduction
Pluripotent stem cells (PSCs) are characterized by their pluripotency and self-renewal capacity, making them attractive candidates for regenerative medicine. However, their clinical translation has been limited by concerns regarding tumorigenicity, particularly the formation of teratomas following transplantation.
The prevailing perception of PSC-associated cancer risk originates from early studies demonstrating teratoma formation in vivo. Yet, these studies largely rely on immunodeficient animal models, raising questions about their relevance to physiological conditions in humans.
In parallel, a growing body of literature has explored the interaction between embryonic microenvironments and cancer cells, revealing unexpected tumor-suppressive and reprogramming effects. These findings challenge the traditional view of PSCs as inherently tumorigenic and suggest a more complex biological role.
This paper aims to:
- Reevaluate the evidence for PSC tumorigenicity
- Examine the role of host immune status
- Explore PSC-mediated anticancer mechanisms
- Discuss translational and clinical implications
Tumorigenicity of PSCs: Evidence and Limitations
Classical Evidence of Teratoma Formation
Seminal work by Blum and Benvenisty (2008) demonstrated that undifferentiated human PSCs can form teratomas when transplanted in vivo. Teratomas are benign tumors composed of differentiated tissues from multiple germ layers, reflecting the pluripotent nature of PSCs.
However, these experiments were conducted under conditions that do not reflect normal physiological immunity, typically involving severely immunocompromised hosts.
Role of the Immune System
Subsequent analyses have emphasized the critical role of host immunity in determining PSC fate.
Knoepfler (2009) highlighted that the absence of teratoma formation in some models may result from immune-mediated rejection, rather than intrinsic safety of the cells. Conversely, teratoma formation is consistently observed in immunodeficient settings.
Experimental work by Dressel et al. further demonstrated that:
- Teratomas formed in ~95% of immunodeficient recipients
- No tumors developed in immunocompetent hosts
These findings suggest that:
- PSC tumorigenicity is context-dependent
- The immune system acts as a natural safeguard
Attempts to Circumvent Immune Clearance
Rong (2012) and other groups attempted to genetically modify PSCs to evade immune detection, thereby promoting engraftment. These efforts indirectly confirm that immune surveillance is the primary barrier preventing PSC persistence and tumor formation.
Mechanisms of Action: Beyond Engraftment
All these efforts were motivated by the traditional paradigm which assumes that PSCs must engraft and differentiate to exert therapeutic effects. However, we now have plenty of evidence that support a paracrine model of action.
PSCs secrete exosomes containing:
- MicroRNAs
- Proteins
- Regulatory molecules
These exosomes:
- Transfer biological signals to recipient cells
- Modulate gene expression
- Influence cellular behavior without requiring cell integration
This mechanism negates the necessity for long-term cell survival and may significantly mitigate tumorigenic risk.
Antitumor Effects of PSC-Derived Factors
Reprogramming of Cancer Cells
Studies by Postovit et al. (2007, 2008) demonstrated that exposure of aggressive cancer cells to embryonic microenvironments results in:
- Downregulation of oncogenic pathways (e.g., Nodal)
- Increased apoptosis
- Reduced tumorigenicity
A key mediator identified in these studies is Lefty, a protein uniquely secreted by PSCs that antagonizes Nodal signaling.
MicroRNA Regulation
Further investigations by Costa et al (2009) identified microRNAs such as miR-302a as critical regulators of tumor cell plasticity. These molecules target pathways involved in:
- Cell proliferation
- Differentiation
- Metastatic potential
Suppression of Tumor Aggressiveness
Additional studies by Tarasewizc (2018) and He (2016), have shown that PSC-conditioned media can:
- Reduce tumor proliferation and invasion
- Inhibit migration and metastasis
- Suppress key oncogenic pathways such as Stat3 signaling
Collectively, these findings suggest that PSC-derived factors create a tumor-suppressive microenvironment.
PSCs in Cancer Prevention: Vaccination Models
The antigenic similarity between embryonic and tumor cells has led to the exploration of PSCs as cancer vaccines.
Multiple studies have demonstrated that PSC-based vaccination:
- Induces robust CD8+ T-cell responses
- Generates long-term immunological memory
- Reduces tumor incidence and progression
These effects have been observed across multiple cancer models, including:
- Lung cancer, Yaddanapudi (2012)
- Ovarian cancer, Zhang (2012)
- Colon cancer, Li (2009)
Notably, PSCs appear to provide broader protection than induced pluripotent stem cells (iPSCs), potentially due to differences in antigen expression.
Clinical Observations
Longitudinal monitoring of tumor markers (e.g., CEA, CA125, PSA) in treated individuals suggests:
- A trend toward decreased marker levels
- Improved physiological recovery following conventional therapies
While these observations are not derived from controlled clinical trials, they support the hypothesis that ESC-based approaches may:
- Be safe in patients with cancer
- Contribute to systemic regulation
Further controlled studies are required to validate these findings.
Discussion
The longstanding concern regarding PSC tumorigenicity appears to be overstated when extrapolated to immunocompetent systems. Evidence suggests that:
- Tumor formation is largely restricted to artificial experimental conditions
- PSCs are subject to immune regulation in vivo
- Their primary biological activity is mediated through signaling rather than engraftment
Moreover, PSC-derived factors demonstrate consistent anticancer properties, including reprogramming of malignant cells and modulation of tumor microenvironments.
Conclusion
Current evidence supports a reassessment of the safety profile of pluripotent stem cells. In immunocompetent contexts, PSCs exhibit:
- Low tumorigenic risk
- Significant paracrine activity
- Potential antitumor and preventive effects
These findings justify further investigation into PSC-based therapies, particularly those leveraging cell-free derivatives such as exosomes, which may offer a favorable balance between efficacy and safety.
References
- Blum B, Benvenisty N. Adv Cancer Res. 2008
- Knoepfler PS. Stem Cells. 2009
- Rong Z et al. Biol Chem. 2012
- Dressel R et al.
- Postovit LM et al. J Cell Biochem. 2007
- Postovit LM et al. 2008
- Costa FF et al. Epigenomics 2009
- Tarasewicz E et al. Cancer Biol Ther. 2018
- He N et al. Stem Cell Res Ther. 2016
- Yaddanapudi K et al. PLoS One. 2012
- Zhang Z et al. Int J Mol Med. 2012
- Li Y et al. Stem Cells. 2009
